Application of compound medicine composition in preparation of medicine for treating interstitial pneumonia

A composition and interstitial technology, applied in the field of compounds, to achieve significant curative effect advantages and obvious synergistic effects

Pending Publication Date: 2022-05-31
CHINA PHARM UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Currently, there is no 5-HT 2A Use report of R antagonist and / or 5-HT synthesis inhibitor for treating IP

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound medicine composition in preparation of medicine for treating interstitial pneumonia
  • Application of compound medicine composition in preparation of medicine for treating interstitial pneumonia
  • Application of compound medicine composition in preparation of medicine for treating interstitial pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Changes in the expression of 5-HT synthase, 5-HT2A receptor and MAO-A in lung tissue during BLM-induced IP in mice

[0036] 1.1 Experimental method

[0037] Male C57BL / 6 mice (clean grade), weighing 20-24 g, were used in the experiment. The animals were housed in ordinary rat cages, maintained at room temperature of 24 ± 2 °C, light control ensured 12 hours of light and dark conditions, and fed with ordinary water. After the animals were anesthetized, bleomycin (BLM, 3.5 mg / kg) was administered intratracheally by puncture to establish an animal model of interstitial pneumonia (IP), and the control group was given an equal volume of normal saline. After 21 days of modeling, the animals were sacrificed, and the lung tissue was taken for formalin fixation, tissue sectioning, and immunohistochemical staining to detect the 5-HT 2A receptor (5-HT 2A receptor) in the lung tissue. 2A R), protein expression of 5-HT synthase Tph1 and AADC, 5-HT degrading enzyme monoamine oxidase...

Embodiment 2

[0041] Therapeutic effects of drugs on IP in BLM-induced mice

[0042] Comparing the therapeutic effects of sarpogrelate hydrochloride (SH) and carbidopa (CDP) in combination and each alone on BLM-induced interstitial pneumonia (IP) in mice, so as to verify the effect of SH and CDP co-administration on interstitial pneumonia (IP) in mice. Synergistic effects of IP therapy.

[0043] 2.1 Experimental method

[0044] (1) Animal handling

[0045] C57BL / 6 mice (clean grade) were used in the experiment, weighing 20-24 g. The animals were housed in ordinary rat cages, maintained at room temperature of 24 ± 2 °C, light control ensured 12 hours of light and dark conditions, and fed with ordinary water.

[0046] The animals were randomly divided into 7 groups (8 animals in each group): control group, BLM-induced IP model group (BLM model group), IP model SH treatment group (BLM+SH group), IP model SH+CDP compound treatment group (SH: CDP) 3 kinds of compound prescriptions (respective...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a compound medicine composition taking sarpogrelate and carbidopa as active ingredients in preparation of a medicine for treating interstitial pneumonia, the compound medicine composition can inhibit 5-hydroxytryptamine (5-HT) synthetase and 5-HT2A receptor (5-HT2AR) activity of lung tissue cells (including macrophages), and can inhibit the activity of sarpogrelate and carbidopa. Specifically, the 5-HT2AR antagonist sarpogrelate and the 5-HT synthetic inhibitor carbidopa form a compound within a certain weight ratio range, and the composition has an obvious synergistic effect on treatment of interstitial pneumonia and has an obvious treatment effect.

Description

technical field [0001] The present invention relates to the application of a class of compounds, in particular to the application of a compound pharmaceutical composition in the preparation of drugs for treating interstitial pneumonia. Background technique [0002] Interstitial pneumonia (IP) is caused by various factors such as radiation, chemicals (bleomycin (BLM), silica, asbestos, etc.), infection (respiratory virus, bacteria, etc.), etc. Inflammatory and fibrotic lesions of the lungs. The etiology that can cause IP is very wide. According to the etiology, it is divided into rheumatic immune diseases of known etiology, drug or treatment-related diseases (antiarrhythmic drugs, chemotherapy drugs, paraquat, sulfasalazine, radiotherapy, etc.), occupational and environmental diseases (silicosis, asbestosis, coal pneumoconiosis, etc.), and primary diseases of unknown etiology (sarcoidosis, lymphangiomuscular neoplastic disease, eosinophilic pneumonia, etc.) or idiopathic di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/225A61K31/198A61P11/00
CPCA61K31/225A61K31/198A61P11/00A61K2300/00
Inventor 傅继华
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap